Determining expression of miRNAs that potentially regulate STAT5A and 5B in dasatinib-sensitive K562 cells

Turkish Journal of Biology = Türk Biyoloji Dergisi
Asu Fergün YilmazFiliz Vural

Abstract

In the era of tyrosine kinase inhibitors, resistance still constitutes a problem in chronic myeloid leukemia (CML) patients; thus, new pathway-specific inhibitors like miRNAs have become important in the treatment of refractory patients. There are no satisfying data regarding the miRNAs and anti-miRNA treatment targeting STAT5A and 5B. In this study, we first researched the effect of dasatinib on apoptosis in the CML cell line K562. The expressions of miRNAs possibly targeting both STAT5A and 5B were then determined. The down- and upregulation of the miRNAs were compared using the ΔΔCT method. At the last stage of the study, we used a new primer probe in order to validate the results. The level of hsa-miR-940 was decreased 4.4 times and the levels of hsa-miR-527 and hsa-miR-518a-5p were increased 12.1 and 8 times, respectively, in the dasatinib-treated group when compared to the control group. We detected similar results in the validation step. As a conclusion, we determined the expression profiles of miRNAs targeting STAT5A and 5B that had an important role in the pathogenesis of CML. The data obtained could lead to determining new therapeutic targets for CML patients.

References

Jun 13, 2000·Oncogene·T BowmanR Jove
Mar 1, 2002·The New England Journal of Medicine·Hagop KantarjianUNKNOWN International STI571 CML Study Group
Feb 18, 2004·Nature Reviews. Cancer·Hua Yu, Richard Jove
Mar 17, 2004·Journal of Cell Science·Jason S RawlingsDouglas A Harrison
Oct 18, 2005·Leukemia Research·Shakti H RamkissoonNeal S Young
Oct 25, 2006·Nature Reviews. Cancer·George A Calin, Carlo M Croce
Nov 3, 2007·The Lancet Oncology·Jane F Apperley
Dec 7, 2007·Proceedings of the National Academy of Sciences of the United States of America·Shuangli MiJianjun Chen
Mar 1, 2008·Proceedings of the National Academy of Sciences of the United States of America·Ramiro GarzonBrunangelo Falini
Dec 17, 2008·Molecular Cancer Research : MCR·Xabier AgirreFelipe Prósper
May 5, 2009·Cell·Riccardo SpizzoGeorge A Calin
Aug 12, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mustafa BenekliMeir Wetzler
May 13, 2010·Haematologica·Stéphane FlamantJohn E J Rasko
Dec 3, 2010·The Journal of Pathology·Thalia A FaraziThomas Tuschl
Jun 4, 2011·Journal of Cell Communication and Signaling·Sukanya SureshAlexandra E Irvine
Apr 19, 2012·PloS One·Oshrat Hershkovitz RokahOfer Shpilberg
Jul 31, 2012·Biochemical and Biophysical Research Communications·Li LiuYingmin Liang
May 30, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Burçin Tezcanlı KaymazBuket Kosova
Feb 24, 2015·Cancer Letters·Oshrat Hershkovitz-RokahGalit Granot
May 9, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Burçin Tezcanlı KaymazBuket Kosova Can
Aug 25, 2015·Clinical Lymphoma, Myeloma & Leukemia·Ceyda Tunakan DalgıçGüray Saydam
Mar 8, 2016·Laboratory Investigation; a Journal of Technical Methods and Pathology·Yuan ShiYingyong Hou

❮ Previous
Next ❯

Citations

Jun 26, 2021·Molecular Therapy. Nucleic Acids·Hongxiang LiShiwei Duan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis